Quotes
Change: % | Volume: 0
| Ticker Symbol: | DARA |
|---|---|
| Exchange: | NASD |
| Contact Info: | 8601 Six Forks Road Raleigh 27615 919-872-5578 |
| CEO/President: | John Didsbury |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | DARA BIOSCIENCES, INC. is a Raleigh, North Carolina -based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for europathic pain, metabolic diseases including type 2 diabetes, and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC. |
| Shares Outstanding: | 27,630 (000) | Market Value: | 14,750 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 2.72% | Number of Inst.Shareholders: | 9.03% |
| Last Quarter Sales: | 0.00 ($Mil.) | Last Quarter Net Income: | -3.91 ($Mil.) |
| Last Quarter EPS: | N/C | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.20 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Partners   
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
